Widely used:Recently Viewed
Clear All
Value Research Rating
Quality Score 
10/10
Growth Score
7/10
Valuation Score
3/10
Momentum Score
8/10
₹48,279 Cr
75.43
24.52
45.53
0
45.37
--
1.12
116.23
44
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Glaxosmithkline Pharma
| 50.32 | -0.71 | 13.79 | 95.23 | 23.41 | 17.42 | 8.44 |
|
BSE Healthcare
| 37.44 | 5.95 | 19.45 | 53.33 | 17.79 | 27.34 | 12.05 |
|
BSE Mid Cap
| 31.29 | 3.73 | 9.65 | 48.04 | 25.33 | 29.34 | 17.32 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Glaxosmithkline Pharma
| 43.94 | -24.93 | 9.01 | -0.48 | 7.50 | 23.05 | -8.81 |
|
BSE Mid Cap
| 45.53 | 1.38 | 39.18 | 19.87 | -3.05 | -13.31 | 48.13 |
|
BSE Healthcare
| 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 | 0.49 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Our rating system has guided millions of investors in the past 20 years.
₹48,279.03 Cr
₹3,506.70 Cr
₹640.04 Cr
₹1,876.44 Cr
₹0.00 Cr
75.00%
High
₹1,385.05 - 3,088.00
₹10.00
16,94,06,034
BSE: 500660, NSE: GLAXO
Mumbai, Maharashtra
www.gsk-india.com
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis,... hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin and dry skin associated with redness and itch. Further, it develops products for infectious diseases, HIV, oncology, and immunology. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India. Read more
The total asset value of Glaxosmithkline Pharmaceuticals Ltd stood at ₹ 3,557 Cr as on 30-Jun-24
The share price of Glaxosmithkline Pharmaceuticals Ltd is ₹2,853.25 (NSE) and ₹2,848.95 (BSE) as of 09-Sep-2024 IST. Glaxosmithkline Pharmaceuticals Ltd has given a return of 23.41% in the last 3 years.
Glaxosmithkline Pharmaceuticals Ltd has a market capitalisation of ₹ 48,279 Cr as on 09-Sep-2024. As per Value Research classification, it is a Mid Cap company.
The P/B ratio of Glaxosmithkline Pharmaceuticals Ltd is 24.52 times as on 09-Sep-2024, a 253% premium to its peers’ median range of 6.95 times.
The P/E ratio of Glaxosmithkline Pharmaceuticals Ltd is 75.43 times as on 09-Sep-2024, a 66% premium to its peers’ median range of 45.53 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Glaxosmithkline Pharmaceuticals Ltd and enter the required number of quantities and click on buy to purchase the shares of Glaxosmithkline Pharmaceuticals Ltd.
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines comprising NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and TRELEGY ELLIPTA for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, which are antibiotics to treat bacterial infections; CALPOL for treatment of mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment and prevention of specific bacterial skin infections; BETNOVATE for skin conditions which require relief of inflammation; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin and dry skin associated with redness and itch. Further, it develops products for infectious diseases, HIV, oncology, and immunology. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.
The prominent promoters of Glaxosmithkline Pharmaceuticals Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
GLAXO GROUP LIMITED |
35.99%
|
|
GLAXOSMITHKLINE PTE LIMITED |
28.1%
|
|
ESKAYLAB LIMITED |
6.94%
|
|
BURROUGHS WELLCOME INTERNATIONAL LIMITED |
3.97%
|
The chairman of the company is R S Karnad, and the managing director is Bhushan Akshikar.
There is no promoter pledging in Glaxosmithkline Pharmaceuticals Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
63,637
|
|
|
44,902
|
|
|
41,901
|
|
|
36,106
|
| Glaxosmithkline Pharmaceuticals Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
45.37
|
|
Operating margin(%)
|
26.4
|
|
Net Margin(%)
|
17.64
|
|
Dividend yield(%)
|
1.12
|
Yes, TTM profit after tax of Glaxosmithkline Pharmaceuticals Ltd was ₹640 Cr.
Stocks 
Glaxosmithkline Pharmaceuticals Ltd.
₹21.65
